The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Novartis
PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.
 
Maud Toulmonde
No Relationships to Disclose
 
Thomas Grellety
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Lilly; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Other Relationship - Innate Pharma
 
Axel Le Cesne
Honoraria - Amgen; Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Nicolas Penel
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag
 
Sophie Piperno-Neumann
No Relationships to Disclose
 
Francois Bertucci
No Relationships to Disclose
 
Christine Chevreau
No Relationships to Disclose
 
Emmanuelle Bompas
No Relationships to Disclose
 
Sophie Cousin
No Relationships to Disclose
 
Sabrina Sellan-Albert
No Relationships to Disclose
 
Marina Pulido
No Relationships to Disclose
 
Carine A. Bellera
No Relationships to Disclose
 
Barbara Lortal
No Relationships to Disclose
 
Simone Mathoulin-Pélissier
No Relationships to Disclose
 
Antoine Italiano
No Relationships to Disclose